{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:09:22Z","timestamp":1787738962629,"version":"build-2784847793"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Cancer Center Research and Development Funds","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with peripheral T-cell lymphoma demonstrated a poor prognosis after obtaining a complete response with induction treatment compared to those with B-cell lymphoma. Once it relapsed, curative treatment is frequently limited to invasive treatments with significant treatment-related mortality, including allogeneic stem cell transplantation. The limitations of these treatment choices indicate the necessity for developing optimal consolidation therapies to prevent relapse. This multicenter randomized phase III trial aims to confirm the superiority of the high-dose therapy with autologous stem cell transplantation over observation alone in terms of progression-free survival for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy. A total of 140 patients from 52 hospitals will be enrolled in Japan over 5.5\u00a0years. This trial is registered in the Japan Registry of Clinical Trials as jRCTs031240169 (https:\/\/jrct.niph.go.jp\/latest-detail\/jRCTs031240169).<\/jats:p>","DOI":"10.1093\/jjco\/hyae144","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T19:36:37Z","timestamp":1729366597000},"page":"183-188","source":"Crossref","is-referenced-by-count":7,"title":["Multicenter randomized phase III study of high-dose therapy with autologous stem cell transplantation versus observation for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy (JCOG2210, TRANSFER study)"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5708-3829","authenticated-orcid":false,"given":"Ryosuke","family":"Kita","sequence":"first","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-9219","authenticated-orcid":false,"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine , Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Machida","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Sekita","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5100-3863","authenticated-orcid":false,"given":"Keita","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Faculty of Medicine, , Kagoshima ,","place":["Japan"]},{"name":"Kagoshima University , Faculty of Medicine, , Kagoshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-0656","authenticated-orcid":false,"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center , Aichi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japan Clinical Oncology Group Lymphoma Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"2025101605113280800_ref1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-cell lymphoma project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025101605113280800_ref2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12185-013-1383-z","article-title":"A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology study group","volume":"98","author":"Torimoto","year":"2013","journal-title":"Int J Hematol"},{"key":"2025101605113280800_ref3","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2011-08-374371","article-title":"Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan","volume":"119","author":"Tokunaga","year":"2012","journal-title":"Blood"},{"key":"2025101605113280800_ref4","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"2025101605113280800_ref5","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"2025101605113280800_ref6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2147\/OTT.S189825","article-title":"Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2025101605113280800_ref7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"2025101605113280800_ref8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"2025101605113280800_ref9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"key":"2025101605113280800_ref10","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J"},{"key":"2025101605113280800_ref11","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"2025101605113280800_ref12","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025101605113280800_ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.","volume-title":"Eur J Haematol","author":"Rodr\u00edguez","year":"2007"},{"key":"2025101605113280800_ref14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025101605113280800_ref15","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"key":"2025101605113280800_ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume-title":"Cancer","author":"Park","year":"2019"},{"key":"2025101605113280800_ref17","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1111\/cas.14604","article-title":"R-CHOP-14 versus R-CHOP-14\/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study","volume":"111","author":"Kagami","year":"2020","journal-title":"Cancer Sci"},{"key":"2025101605113280800_ref18","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/cas.13719","article-title":"R-high-CHOP\/CHASER\/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY","volume":"109","author":"Ogura","year":"2018","journal-title":"Cancer Sci"},{"key":"2025101605113280800_ref19","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1111\/cas.15849","article-title":"Long-term follow-up after R-high CHOP\/CHASER\/LEED with auto-PBSCT in untreated mantle cell lymphoma-final analysis of JCOG0406","volume":"114","author":"Ogura","year":"2023","journal-title":"Cancer Sci"},{"key":"2025101605113280800_ref20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00277-016-2891-8","article-title":"Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP\/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment","volume":"96","author":"Kitahara","year":"2017","journal-title":"Ann Hematol"},{"key":"2025101605113280800_ref21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2307\/2530299","article-title":"Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint","volume":"38","author":"Schoenfeld","year":"1982","journal-title":"Biometrics"},{"key":"2025101605113280800_ref22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0197-2456(82)90022-8","article-title":"An aid to data monitoring in long-term clinical trials","volume":"3","author":"Halperin","year":"1982","journal-title":"Control Clin Trials"},{"key":"2025101605113280800_ref23","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/sim.4780121516","article-title":"Applying Bayesian ideas in drug development and clinical trials","volume":"12","author":"Spiegelhalter","year":"1993","journal-title":"Stat Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/2\/183\/59895185\/hyae144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/2\/183\/59895185\/hyae144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:11:39Z","timestamp":1760605899000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/2\/183\/7828043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,10,19]]},"published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae144","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,10,19]]}}}